PMN vs. BDTX, ZURA, TSVT, TIL, ALGS, TNYA, LPTX, XBIT, ATOS, and ANRO
Should you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Black Diamond Therapeutics (BDTX), Zura Bio (ZURA), 2seventy bio (TSVT), Instil Bio (TIL), Aligos Therapeutics (ALGS), Tenaya Therapeutics (TNYA), Leap Therapeutics (LPTX), XBiotech (XBIT), Atossa Therapeutics (ATOS), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry.
ProMIS Neurosciences vs.
ProMIS Neurosciences (NASDAQ:PMN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.
Black Diamond Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 591.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than ProMIS Neurosciences.
ProMIS Neurosciences has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500.
Black Diamond Therapeutics' return on equity of -68.08% beat ProMIS Neurosciences' return on equity.
Black Diamond Therapeutics received 49 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 69.86% of users gave Black Diamond Therapeutics an outperform vote.
ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Black Diamond Therapeutics had 1 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for ProMIS Neurosciences. Black Diamond Therapeutics' average media sentiment score of 0.76 beat ProMIS Neurosciences' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
50.1% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 4.4% of ProMIS Neurosciences shares are held by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Black Diamond Therapeutics beats ProMIS Neurosciences on 12 of the 15 factors compared between the two stocks.
Get ProMIS Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProMIS Neurosciences Competitors List
Related Companies and Tools
This page (NASDAQ:PMN) was last updated on 1/21/2025 by MarketBeat.com Staff
